Awards

$99.3K

Optimization of the angiogenic potential of multipotent adult progenitor cells

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/01/10 - 07/31/12
PI: Robert Deans

DESCRIPTION (provided by applicant): Peripheral Vascular Disease (PVD) results from chronic loss of the oxygen supply to the lower limbs due to arterial blockage. Loss of oxygen to these tissues can result in pain, ulcers, infection and limb amputation in patients. PVD affects up to 12% of the population globally with increased risk in patients ...

$392K

Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-07-281
Budget: 11/01/09 - 10/31/11
PI: James Edwin Carroll

DESCRIPTION: The specific objective of this STTR Phase II research and development project is to provide an optimized cellular therapy regimen for treating hypoxic-ischemic (HI) injury and its related outcomes in neonates. Pre- clinical studies performed in a rat pup model of HI injury as part of the funded Phase I STTR grant, point to benefit w...

$205K

Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-07-281
Budget: 11/01/08 - 10/31/09
PI: James Edwin Carroll

DESCRIPTION: The specific objective of this STTR Phase II research and development project is to provide an optimized cellular therapy regimen for treating hypoxic-ischemic (HI) injury and its related outcomes in neonates. Pre- clinical studies performed in a rat pup model of HI injury as part of the funded Phase I STTR grant, point to benefit w...

$392K

Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-07-281
Budget: 11/01/08 - 10/31/09
PI: James Edwin Carroll

PROJECT SUMMARY/ABSTRACT The specific objective of this STTR Phase II research and development project is to provide an optimized cellular therapy regimen for treating hypoxic-ischemic (HI) injury and its related outcomes in neonates. Pre- clinical studies performed in a rat pup model of HI injury as part of the funded Phase I STTR grant, point ...

$205K

Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-07-81
Budget: 09/30/07 - 10/31/08
PI: Cesario V Borlongan

DESCRIPTION: The specific objective of this STTR Phase II research and development project is to provide an optimized cellular therapy regimen for treating hypoxic-ischemic (HI) injury and its related outcomes in neonates. Pre- clinical studies performed in a rat pup model of HI injury as part of the funded Phase I STTR grant, point to benefit w...

$137K

Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/06 - 08/31/07
PI: James Edwin Carroll

DESCRIPTION (provided by applicant): The emergence of technologies enabling isolation of adult stem cells has allowed evaluation of cell therapeutics for central nervous system disorders with a path for clinical development. Much promise has been shown using stem cells in acute disease models such as stroke or hypoxic injury to the brain, and as...

$100K

In-vitro generation of cardiomyocytes from MAPC

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/04 - 08/31/06
PI: Wouter J Van'T Hof

DESCRIPTION (provided by applicant): The development and institution of stem cell and tissue engineering methodologies hold the potential to target many of the most significant cardiovascular diseases and have a dramatic impact on the treatment of one of the leading causes of death in the United States healthcare system. The current proposal is ...

$349K

Genome-Wide Growth Factor Discovery in the CNS

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/04 - 08/31/06
PI: John J Harrington

DESCRIPTION (provided by applicant): We propose to carry out a rapid genome-wide search for new mitogens and survival factors for stem and precursor cells of CNS, potentially doubling or more the number of known CNS mitogenic and survival factors over the course of two years. To do this, a novel protein expression technology, called Random Activ...

$99.9K

Small Molecular Inhibitors of Artemis as Radiosensitizer

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/04 - 07/31/06
PI: John J Harrington

DESCRIPTION (provided by applicant): Recent advances in our understanding of DNA repair mechanisms have led to the identification of the DNA repair specific nuclease, Artemis. Mutations in this enzyme do not affect viability, but enhance cellular sensitivity to ionizing radiation through the prevention of non-homologous-end-joining (NHEJ)-based ...

$99.9K

Autologous cell therapy with SMC modified MAPCs

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/02/04 - 08/31/04
PI: John J Harrington

DESCRIPTION (provided by applicant): The objective of the current proposal is to establish genetic modification of Multipotent Adult Progenitor Cells (MAPCs) with Synthetic Microchromosome vectors (SMCs) as a strategy for application in autologous cell based therapy of Hurler's Syndrome (Mucopolysaccharidosis Type 1). Multipotent Adult Progenito...

Load More